quences performed immediately and 1.5, 3.5, 4.5, 9.5, and 11.5 minutes after administration of a single dose of Gd (0.2 ml/kg, 1 ml/sec, MEDRAD Inc.) in 21 patients (11 women, 10 men; mean age 45 years, range 24-68 years), suffering from medium-to large-sized VS (mean diameter 24 mm, range diameter 10-48 mm). With respect to radiological classification in homogeneous, heterogeneous, and cystic tumors, the most representative images of the dynamic series were used (T1-weighted VIBE, TR 9.82 msec, TE 4.92 msec, SL 1 mm, FOV 130 × 160 mm, matrix 135 × 256 pixels, 12° FA, 135 phase-encoding steps).
An ROI analysis was performed as described by Wintersperger et al. 33 The VS volume was manually segmented in the last image of the series with clearly delineated tumor. This volume was then transferred to all other image series, which were coregistered to correct minor changes due to patient movement (MIPAV software, Center for Information Technology). Segmented volume was used as ROI tumor . In addition, a homogeneous area of enhancement within normal brain was manually defined (ROI brain , size equal to ROI tumor ), as well as an artifact-free region within the surrounding air (ROI air ), as large as the extent of the images permitted. Signal-to-noise (SNR) and contrast-to-noise ratios (CNR) were calculated according to the following formulas: SNR brain,t = SI brain,t / SD air,t SNR tumor,t = SI tumor,t / SD air,t CNR = (SI tumor,t − SI brain,t ) / SD air,t where SI tumor,t is the average signal intensity in ROI tumor , SI brain,t the average brain signal intensity in ROI brain , and SD air,t the standard deviation of the background signal in ROI air at time point t.
To objectively estimate the volume of central areas without signal enhancement at each time point, areas within the tumor with CNR values below 5 were identified. The threshold value of 5 corresponds to the lower limit of visually obvious contrasts, 1 that is, voxels with CNR values below 5 are not discernible from normal brain tissue without contrast agent uptake.
Influence of image acquisition time on SNR, CNR, and size of areas without signal enhancement was statistically analyzed using the Friedman test; differences between successive images were tested using the Wilcoxon rank sum test (MATLAB software, The MathWorks, Inc.).
Results
In the investigated sample of patients, all 3 subtypeshomogenous, heterogeneous, and cystic-were present: 6 patients (28.5%) presented with homogeneous tumors, 13 (62%) with heterogeneous, and 2 (9.5%) with cystic tumors, but subtype did not have any noticeable influence on the contrast agent uptake behavior.
Time of image acquisition after contrast agent administration did not have any detectable influence on the extent of the enhanced tumor volume. Figures 2 and 3 show 2 examples.
Volume of Nonenhancing Areas
In contrast to the stability of overall tumor size, interior appearance changed considerably over time. At early time points, low SNR and CNR allowed only limited evaluation of NEAs. Due to incomplete contrast agent uptake at this stage, a large proportion of the tumor did not reach a minimum CNR of 5 and was not distinguishable from normal nonenchancing brain tissue (expressed by large volume values in Table 1 and Fig. 4 ). At later time points, contrast agent enhancement allowed clear identification of NEAs, however, the appearance of these areas was not stable. In all patients, volumes of these tumor portions decreased; the median NEA at the last time point was only 11% of that in the images obtained 1.5 minutes after contrast agent administration. Compared to images at 1.5 minutes, the first time point after the initial contrast agent uptake, NEA volumes decreased considerably to median values of 36% at 3.5 minutes and 34% at 4.5 minutes. Further decrease was still observed at 9.5 and 11.5 minutes, when the median NEA volumes had reached, respectively, 9% and 3% of the NEA volumes at 1.5 minutes.
Statistical analysis showed a significant influence of time of image acquisition on the extent of NEAs both when all time points were considered (p < 0.0001, Friedman test) and when analysis was constrained to the last 3 (p < 0.0001). 
Signal-to-Noise Ratio
The SNR values increased from a median value of 14.3 to a maximum of 34.3 at 11.5 minutes after Gd administration, and the largest median increase (72%) was found in the initial phase (up to 1.5 minutes after Gd administration). The difference between the values at 0 and 1.5 minutes was found to be significant (p < 0.0001, Wilcoxon rank sum test, 2-sided) and the difference between the values at 1.5 and 3.5 minutes reached a statistical level of a tendency (p < 0.1), while the remaining differences were not significantly different, when values of successive time points were compared (Fig. 5) . The Friedman test showed a significant influence of time of image acquisition on SNR when all time points were considered (p < 0.0001), as well as when the initial phase was left out and only the last 3 time points (4.5, 9.5, and 11.5 minutes after Gd administration) were included in the statistical analysis (p < 0.0001).
Contrast-to-Noise Ratio
The CNR values also increased over time from a median of 4.3 to 15.9 (Fig. 6) . Again, the largest median increase (117%) was seen at 1.5 minutes after Gd administration. Differences between the values at 0 and 1.5 minutes and between those at 1.5 and 3.5 minutes were found to be statistically significant (p < 0.0001 and p < 0.05, respectively), whereas the differences between sets of values obtained at subsequent successive time points were not. As for SNR, the Friedman test also showed a significant effect of time of image acquisition on CNR both when all time points (p < 0.0001) were considered and when only the last 3 were considered (p < 0.005).
Discussion
Since the introduction of the Gamma Knife for the treatment of VS, 19 there have been ongoing discussions about the criteria for tumor response. Posttreatment MR imaging evaluates tumor size and changes in contrast enhancement. 4, 5, 11, 18, 20, 24 Central tumor hypointensity following radiosurgery has been reported by Selch et * Values represent volumes of the tumors and of the nonenhancing areas (NEAs) of the tumors immediately after Gd administration (0 min) and 1.5, 3.5, 4.5, 9.5, and 11.5 minutes thereafter. 10 for example, described that histopathological examination of a previously irradiated tumor with hemorrhage into cystic VS showed no radiotherapy-induced necrosis.
We conducted the current study because there was a lack of systematic data about contrast agent uptake in VS. We found considerable variation of tumor contrast enhancement on MR imaging over time depending on the delay between contrast administration and image acquisition. Central hypointense tumor portions disappeared almost completely in all but 2 patients during the course of the MR imaging session. The increasing contrast enhancement in tumor areas that were initially nonenhancing could be a consequence of different perfusion and seems to depend on the delay between Gd administration and image acquisition.
Although the current study investigated nonirradiated tumors, we hypothesize that the phenomenon of timedependent changes of contrast enhancement in VS is also present after radiosurgery. Thus too-early image acquisition will show a mixture of this phenomenon and true lack of central enhancement due to necrosis. Therefore, reliability of conclusions drawn from central nonenhancing areas are confounded in such cases.
Our results are supported by findings of Kwon et al.,
18
who reported on 3 patients suffering from expanding cysts of a VS necessitating resection following Gamma Knife surgery. Although MR imaging revealed loss of central enhancement followed by its recurrence, histological examination of resected specimens showed no corresponding changes. In contrast, Szeifert et al. 32 observed histopathological changes in VS after Gamma Knife surgery and suggested that loss of central enhancement might be a result due to necrosis and vascular impairment. Iwai et al.
14 reported on histopathological changes (intratumoral bleeding, foamy macrophages, myxoid degeneration, and necrosis) in a series of 6 patients with VS after failed radiosurgery. Prasad et al.
28 described "a significantly higher incidence of central nonenhancement (75%) in tumors that exhibited an early increase in size than in tumors that did not (46%)." They concluded, "The presence of central nonenhancement may serve as a clue to the fact that any perceived volume change is representative of swelling and not growth." Interpreting these histological and clinical findings in single cases as showing that loss of central enhancement indicates longterm success of radiotherapy or changes in tumor volume is controversial. 16, 19, 24 As clinical implication of our results, changes of contrast enhancement following radiotherapy of VS should be interpreted with caution. Though the value of a loss of central enhancement has been debated, 2, 5, 12, 17, 18, 20, 22, [24] [25] [26] [27] [28] 31, 32 a standardized protocol of image acquisition following radiotherapy of VS has not been established.
An evaluation of changes in central contrast enhancement without a strict protocol concerning the latency of contrast agent administration and image acquisition may not be indicative for effective radiotherapy of VS. The course of contrast enhancement in VS in the posttreatment follow-up examinations after radiotherapy may prove comparable, if a strict protocol is used. In this study of untreated tumors, major changes in contrast enhancement later than 4.5 minutes after Gd administration were only seen in one patient, suggesting higher validity of delayed image acquisition.
In our patient population, there was a relatively high percentage of heterogeneous tumors as compared with findings reported in the literature: 62% versus 30%-40%.
3
This might be explained by the fact that we investigated medium-to large-sized tumors, in which heterogeneous tumor components are frequently found; 3,4,6,11 thus, evaluation of smaller, more homogeneous tumors might be affected less by irregular contrast agent uptake.
Though in some follow-up series 24 MR imaging does not start until at least 5 minutes after bolus injection of contrast agent, a standardized protocol is not established even in academic centers, and timing of data acquisition is frequently not reported. 13, 21, 29 Furthermore, MR imaging follow-up examinations are often performed in nonacademic institutions, possibly resulting in much shorter time intervals, due to economic considerations. Under these circumstances, it is important to know that contrast enhancement of VS generally varies in the first 4.5 minutes after contrast agent administration. For treatment control, we recommend standardized protocol-based identical T1-weighted sequences and strict timing between contrast agent administration and image acquisition. Additional studies should verify this in irradiated VS.
Conclusions
As irregular contrast enhancement with central areas of signal hypointensity occurs in untreated VS, changes in irradiated VS should not necessarily be attributed to radiotherapy alone. So-called "necrotic tumor areas" may be falsely detected because of timing of image acquisition with respect to the administration of contrast medium. A standardized MR imaging protocol with identical timing of image acquisition may therefore increase comparability of contrast uptake in VS.
